Linden Thomas Advisory Services LLC Increases Holdings in Moderna, Inc. (NASDAQ:MRNA)

Linden Thomas Advisory Services LLC boosted its stake in Moderna, Inc. (NASDAQ:MRNA) by 5.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,073 shares of the company’s stock after purchasing an additional 256 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Moderna were worth $505,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. International Assets Investment Management LLC increased its stake in Moderna by 6,528.9% in the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after purchasing an additional 381,808 shares during the period. abrdn plc increased its stake in Moderna by 477.5% in the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock worth $48,091,000 after purchasing an additional 399,843 shares during the period. Invesco Ltd. increased its stake in Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after purchasing an additional 517,683 shares during the period. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD increased its stake in Moderna by 10.5% in the 3rd quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 32,188 shares of the company’s stock worth $3,252,000 after purchasing an additional 3,052 shares during the period. Finally, Cadinha & Co. LLC increased its stake in Moderna by 109.0% in the 4th quarter. Cadinha & Co. LLC now owns 81,838 shares of the company’s stock worth $8,139,000 after purchasing an additional 42,685 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on MRNA shares. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. HSBC reiterated a “reduce” rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Canaccord Genuity Group lifted their price target on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. Finally, William Blair restated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $126.49.

Moderna Stock Down 2.5 %

MRNA stock opened at $106.18 on Friday. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $142.79. The business has a fifty day moving average price of $102.15 and a 200-day moving average price of $93.73. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The stock has a market capitalization of $40.65 billion, a P/E ratio of -8.56 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. During the same quarter in the previous year, the business earned $3.61 earnings per share. The company’s revenue was down 44.9% on a year-over-year basis. Equities analysts forecast that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the completion of the sale, the director now owns 2,131,931 shares in the company, valued at $231,399,790.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the completion of the sale, the director now owns 2,131,931 shares of the company’s stock, valued at $231,399,790.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James M. Mock sold 705 shares of the business’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $101.93, for a total value of $71,860.65. Following the sale, the chief financial officer now directly owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 109,954 shares of company stock worth $11,533,976. 15.70% of the stock is owned by insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.